The hunt for the elusive surrogate marker of sterilizing activity in tuberculosis treatment

American Journal of Respiratory and Critical Care Medicine

Volumn 167, Issue 10, 2003, Pages 1299-1301

  Burman, William J ^a  

^a DENVER PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOSTERILANT; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DISEASE MARKER; DRUG ABSORPTION; DRUG ACTIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; EDITORIAL; HUMAN; INFECTION PREVENTION; MATHEMATICAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SPUTUM ANALYSIS; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RESEARCH; SENSITIVITY AND SPECIFICITY; SERUM BACTERICIDAL TEST; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 0038290334     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.2302003     Document Type: Editorial

References (14)

1. Jindani A, Dore CJ, Mitchison DA. The bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003;167:1348-1354.
2. Jindani A, Baer VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:939-949.
3. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-Weezenbeek CSB, Kim SJ, Chaulet P, et al. Global surveillance for antituberulosis-drug resistance, 1994-1997. N Engl J Med 1998;338:1641-1649.
4. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baez J, Kochi A, Dye C, Raviglione MC. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000;283:2537-2545.
5. The Global Alliance for TB Drug Development. The economics of TB drug development. October 2001. Available from: http://www.tballiance.org/pdf/Economics%20Exec%20Summary%20(final ).pdf
6. Burman WJ. The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review. Am J Med Sci 1997;313:355-363.
7. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Tubercle 1978;59:287-297.
8. Mitchison DA. Understanding the chemotherapy of tuberculosis: current problems. J Antimicrob Chemother 1992:29:477-493.
9. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986;133:423-430.
10. East African/British Medical Research Council. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972:1079-1085.
11. Mitchison D. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993;147:1062-1063.
12. Gillespie SH, Gosling RD, Charalambous BM. A reiterative method for calculating the early bactericidal activity of antituberculosis drugs. Am J Respir Crit Care Med 2002;166:31-35.
13. Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis 1991:143:707-712.
14. Hong Kong Chest Service/British Medical Research Council. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981;1:171-174.